- Home
- MTLS vs CERS Comparison
MTLS vs CERS Comparison
Compare MTLS & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTLS
- CERS
- Stock Information
- Founded
- MTLS 1990
- CERS 1991
- Country
- MTLS Belgium
- CERS United States
- Employees
- MTLS N/A
- CERS N/A
- Industry
- MTLS Computer Software: Prepackaged Software
- CERS EDP Services
- Sector
- MTLS Technology
- CERS Technology
- Exchange
- MTLS Nasdaq
- CERS Nasdaq
- Market Cap
- MTLS N/A
- CERS 347.3M
- IPO Year
- MTLS 2014
- CERS 1997
- Fundamental
- Price
- MTLS $4.79
- CERS $1.38
- Analyst Decision
- MTLS Buy
- CERS Strong Buy
- Analyst Count
- MTLS 1
- CERS 2
- Target Price
- MTLS $9.50
- CERS $3.50
- AVG Volume (30 Days)
- MTLS 201.3K
- CERS 1.5M
- Earning Date
- MTLS 04-24-2025
- CERS 05-01-2025
- Dividend Yield
- MTLS N/A
- CERS N/A
- EPS Growth
- MTLS 106.79
- CERS N/A
- EPS
- MTLS 0.24
- CERS N/A
- Revenue
- MTLS $276,182,835.00
- CERS $180,270,000.00
- Revenue This Year
- MTLS $6.55
- CERS $25.22
- Revenue Next Year
- MTLS $9.21
- CERS $10.08
- P/E Ratio
- MTLS $20.89
- CERS N/A
- Revenue Growth
- MTLS 4.15
- CERS 15.29
- 52 Week Low
- MTLS $4.70
- CERS $1.34
- 52 Week High
- MTLS $9.69
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- MTLS 31.61
- CERS 35.86
- Support Level
- MTLS $4.81
- CERS $1.40
- Resistance Level
- MTLS $5.25
- CERS $1.58
- Average True Range (ATR)
- MTLS 0.16
- CERS 0.08
- MACD
- MTLS 0.08
- CERS -0.00
- Stochastic Oscillator
- MTLS 13.85
- CERS 16.00
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.